These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 22499048)
1. [Allogeneic hematopoietic stem cell transplantation with fludarabine, melphalan, and total body irradiation as a conditioning for elderly patients with myeloid malignancies]. Nakamura Y; Mori T; Kato J; Aisa Y; Nakazato T; Shigematsu N; Okamoto S Rinsho Ketsueki; 2012 Mar; 53(3):318-22. PubMed ID: 22499048 [TBL] [Abstract][Full Text] [Related]
2. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome. Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447 [TBL] [Abstract][Full Text] [Related]
6. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786 [TBL] [Abstract][Full Text] [Related]
7. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768 [TBL] [Abstract][Full Text] [Related]
8. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation. Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846 [TBL] [Abstract][Full Text] [Related]
9. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506 [TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine. Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990 [TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
12. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027 [TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Oran B; Giralt S; Saliba R; Hosing C; Popat U; Khouri I; Couriel D; Qazilbash M; Anderlini P; Kebriaei P; Ghosh S; Carrasco-Yalan A; de Meis E; Anagnostopoulos A; Donato M; Champlin RE; de Lima M Biol Blood Marrow Transplant; 2007 Apr; 13(4):454-62. PubMed ID: 17382251 [TBL] [Abstract][Full Text] [Related]
15. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801 [TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience. Rzepecki P; Sarosiek T; Szczylik C Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840 [TBL] [Abstract][Full Text] [Related]
17. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies. Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013 [TBL] [Abstract][Full Text] [Related]
18. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898 [TBL] [Abstract][Full Text] [Related]
19. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521 [TBL] [Abstract][Full Text] [Related]
20. Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies. Small TN; Young JW; Castro-Malaspina H; Prockop S; Wilton A; Heller G; Boulad F; Chiu M; Hsu K; Jakubowski A; Kernan NA; Perales MA; O'Reilly RJ; Papadopoulos EB Biol Blood Marrow Transplant; 2007 Feb; 13(2):235-44. PubMed ID: 17241929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]